Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277270 · ClinicalTrials.gov registry record · Phase 1
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 6
- Study locations
NCT07277270: Recruiting Phase 1 study of Neoplasms, sponsored by GlaxoSmithKline.
NCT07277270 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 84 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07277270, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Fluorouracil
- DRUG Enzalutamide
- DRUG GSK5764227
- DRUG leucovorin
Study Locations (6)
Other
- GSK Investigational Site - Barcelona
- GSK Investigational Site - Madrid
- GSK Investigational Site - Madrid
- GSK Investigational Site - Málaga
New York
- GSK Investigational Site - Lake Success
Queensland
- GSK Investigational Site - Tugun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2028-09-29 |
| Phase | Phase 1 |
What NCT07277270 shows while recruiting
NCT07277270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT07277270 lists 6 locations in 3 states (Other, New York, Queensland).
Frequently Asked Questions
What is clinical trial NCT07277270 about?
NCT07277270 is a clinical study titled "A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors". The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it ...
What is the current status of trial NCT07277270?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2025-12-03. Estimated completion is 2028-09-29.
What conditions does trial NCT07277270 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT07277270?
The interventions under investigation include: Bevacizumab (DRUG), Fluorouracil (DRUG), Enzalutamide (DRUG), GSK5764227 (DRUG), leucovorin (DRUG).
Who is sponsoring clinical trial NCT07277270?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277270 being conducted?
This trial has 6 study locations across New York, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07277270's enrollment target sits among peer trials
84 77th of 158 higher than 81 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI